|
|
| | dynorphin amide (1-13), Ala(2)-(5-F-Phe)(4)- Basic information |
| Product Name: | dynorphin amide (1-13), Ala(2)-(5-F-Phe)(4)- | | Synonyms: | dynorphin amide (1-13), Ala(2)-(5-F-Phe)(4)-;Dynorphin A (swine), 2-D-alanine-4-(2,3,4,5,6-pentafluoro-L-phenylalanine)-13-L-lysinamide-14-de-L-tryptophan-15-de-L-aspartic acid-16-de-L-asparagine-17-de-L-glutamine- (9CI);Dafphedyn | | CAS: | 111846-43-6 | | MF: | C76H124F5N25O14 | | MW: | 1706.95 | | EINECS: | | | Product Categories: | | | Mol File: | 111846-43-6.mol |  |
| | dynorphin amide (1-13), Ala(2)-(5-F-Phe)(4)- Chemical Properties |
| | dynorphin amide (1-13), Ala(2)-(5-F-Phe)(4)- Usage And Synthesis |
| Description | Dafphedyn, [D-Ala2, (F5) Phe4]-dynorphin 1-13-NH2 (DAFPHEDYN) is a potent analog of dynorphin 1-13. Intracerebroventricular administration of the dynorphin analog, [D-Ala2,(F5)Phe4]-dynorphin 1-13-NH2 (DAFPHEDYN) in rats produced diuresis and profound analgesia. Both effects were antagonized by central administration of naltrexone or naloxone. Intravenous administration of 10, 25, and 50 mg/kg of DAFPHEDYN failed to induce diuresis. The increased potency of DAFPHEDYN was apparent from the failure of an equal dose of the parent compound (dynorphin 1-13) to produce diuresis and the failure of [D-Ala2]-dynorphin 1-13-NH2 to produce analgesia. Radioligand binding studies indicated the DAFPHEDYN retains the same degree of kappa selectivity as the parent compound (dynorphin 1-13) though a drop in affinity occurred. DAFPHEDYN may be of significant interest because it retains the essential pharmacology of the parent compound and exhibits marked in vivo potency. |
| | dynorphin amide (1-13), Ala(2)-(5-F-Phe)(4)- Preparation Products And Raw materials |
|